Disorders of Calcium Metabolism

  • Theresa A. Guise
  • Gregory R. Mundy

Abstract

The extracellular fluid (or plasma) calcium concentration is tightly controlled by a complex homeostatic mechanism involving fluxes of calcium across the kidney, bone, and gut. These fluxes are regulated by three major hormones: parathyroid hormone (PTH), calcitonin, and 1,25dihydroxyvitamin D (1,25(OH)2D3). Important cellular functions, such as those listed in Table 1, are dependent on the maintenance of the extracellular calcium concentration within a narrow range (1). Disruption of this finely tuned system results in disorders of calcium metabolism that have predictable effects on these essential physiologic functions and result in the signs and symptoms associated with hypercalcemia and hypocalcemia.

Keywords

Parathyroid Gland Primary Hyperparathyroidism Parathyroid Adenoma Parathyroid Carcinoma Osteoclastic Bone Resorption 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mundy GR: Calcium Homeostasis: Hypercalcemia and Hypocalcemia, 2nd ed. Martin Dunitz, London, 1990.Google Scholar
  2. 2.
    Mallette LE: Regulation of blood calcium in humans. Endocrinol Metabol Clin North Am 18 (3): 601–610, 1989.Google Scholar
  3. 3.
    Barger-Lux MJ, Heaney RP, Recker RR: Time course of calcium absorption in humans: evidence for a colonic component. Calcif Tissue Int 44: 308–311, 1989.PubMedCrossRefGoogle Scholar
  4. 4.
    Yanagawa N, Lee DBN: Renal handling of calcium and phosphorus. In: FL Coe, MJ Favus, eds Disorders of Bone and Mineral Metabolism. Raven Press, New York, Chapter 1, 1992 Google Scholar
  5. 5.
    Aurbach GD, Marx SJ, Spiegel AM: Parathyroid hormone, calcitonin, and the calciferols. In: JD Wilson, DW Foster, Williams Textbook of Endocrinology, 8th ed. WB Saunders, Philadelphia, pp 1397–1517, 1992.Google Scholar
  6. 6.
    Bowers GN, Brassard C, Sena S: Measurement of ionized calcium in serum with ion-selective electrodes: a mature technology that can meet the daily service needs. Clin Chem 32: 1437–1447, 1986.PubMedGoogle Scholar
  7. 7.
    Broadus AE: Physiological functions of calcium, magnesium, and phosphorus and mineral ion balance. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2nd ed. Raven Press, New York, pp 41–46, 1993.Google Scholar
  8. 8.
    Russell J, Lettiere D, Sherwood LM: Direct regulation by calcium of cytoplasmic messenger RNA: coding for pre-pro- parathyroid hormone in isolated bovine parathyroid cells. J Clin Invest 72: 1851–1855, 1983.PubMedCrossRefGoogle Scholar
  9. 9.
    Silver J, Russell J, Sherwood LM: Regulation by vitamin D metabolites of messenger RNA for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82: 4279–4273, 1985.CrossRefGoogle Scholar
  10. 10.
    Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat J Clin Invest 78:1296–1301, 1986 Google Scholar
  11. 11.
    Brown EM: PTH secretion in vivo and in vitro. Miner Electrolyte Metab 8: 130–150, 1982.PubMedGoogle Scholar
  12. 12.
    Brown EM, Gamba G, Riccardi E, Lombardi M, Butters R, Kifor O, Sun A, Hediger M, Lytton J, Hebert SC: Cloning, expression, and characterization of an extracellular Cat’ sensing receptor from bovine parathyroid. Nature 366: 575580, 1993.Google Scholar
  13. 13.
    Pollak MR, Brown EM, Yah-Huei WC, Hevert SC, Marx SJ, Steinmann B, Levi T, Seidman CE, Seidman JG: Mutations in the human Cat+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75: 1297–1303, 1994.CrossRefGoogle Scholar
  14. 14.
    Juppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E, Richards J, Kolakowski LF, Kronenberg HM, Segre GV: A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254: 1024–1026, 1991.PubMedCrossRefGoogle Scholar
  15. 15.
    Segre GV, Niall HD, Habener JF, Potts JT Jr: Metabolism of parathyroid hormone: physiologic and clinical significance. Am J Med 56: 774, 1974.PubMedCrossRefGoogle Scholar
  16. 16.
    Martin KJ, Hruska KA, Greenwalt A, Klahr S, Slatopolsky E: Selective uptake of intact parathyroid hormone by the liver: differences between hepatic and renal uptake. J Clin Invest 58: 781–788, 1976.PubMedCrossRefGoogle Scholar
  17. 17.
    Hruska KA, Korkor A, Martin K, Slatopolsky E: Peripheral metabolism of intact parathyroid hormone: role of liver and kidney and the effect of chronic renal failure J Clin Invest 67:885, 1981 Google Scholar
  18. 18.
    D’Amour P, Huet P, Segre GV, Rosenblatt M: Characteristics of bovine parathyroid hormone extraction by dog liver in vitro. Am J Physiol 241: E208, 1981.PubMedGoogle Scholar
  19. 19.
    Segre GV, Perkins AS, Witters LA, Potts JT: Metabolism of parathyroid hormone by isolated rat Kupffer cells and hepatocytes J Clin Invest 67:449–457, 1981 Google Scholar
  20. 20.
    Segre GV, D’Amour P, Potts JT: Metabolism of radioiodinated bovine parathyroid hormone in the rat Endocrinology 99:1645–1652, 1976 Google Scholar
  21. 21.
    Segre GV, D’Amour P, Hultman A, Potts JT: Effects of hepatectomy, nephrectomy and nephrectomy/uremia on the metabolism of parathyroid hormone in the metabolism of parathyroid hormone in the rat J Clin Invest 67:439–448, 1981 Google Scholar
  22. 22.
    Hruska KA, Kopelman R, Rutherford WE, Klahr S, Slatopolsky E, Greenwalt A, Bascom T, Markham J: Metabolism of immunoreactive parathyroid hormone in the dog: the role of the kidney and the effects of chronic renal disease J Clin Invest 56:39–48, 1975 Google Scholar
  23. 23.
    Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GC, Nozawa-Ung K, Kim Ly, Keutmann HY, Wang C, Potts JT, Segre GV: Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33 (8): 1364–1367, 1987.PubMedGoogle Scholar
  24. 24.
    Deftos LJ: Calcitonin. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2nd ed. Raven Press, New York, pp 70 76, 1993.Google Scholar
  25. 25.
    Barbot N, Calmettes C, Schuffenecker I, Saint-Andre JP, Franc B, Rohmer V, Jallet P, Bigorgne JC: Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screen in hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 78: 114–120, 1994.PubMedCrossRefGoogle Scholar
  26. 26.
    Friedman J, Au W, Raisz LG: Responses of fetal rat bone to thyrocalcitonin in tissue culture. Endocrinology 82: 149–156, 1968.PubMedCrossRefGoogle Scholar
  27. 27.
    Heersche JNM, Marcus R, Aurbach GD: Calcitonin and the formation of 3’,5’-AMP in bone and kidney. Endocrinology 94: 241–247, 1974.PubMedCrossRefGoogle Scholar
  28. 28.
    Moonga BS, Alam AS, Bevis PJ, Avaldi F, Soncini R, Huang CL, Zaidi M: Regulation of cystosolic free calcium in isolated osteoclasts by calcitonin. J Endocrinol 132: 241–249, 1992.PubMedCrossRefGoogle Scholar
  29. 29.
    Chambers TJ, Magnus CJ: Calcitonin alters the behavior of isolated osteoclasts. J Pathol 136: 27–40, 1982.PubMedCrossRefGoogle Scholar
  30. 30.
    Lin HY, Harris TL, Flannery MS, Aruffo A, Kaji EH, Gorn A, Kolakowski LF Jr, Lodish H, Goldring SR: Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254: 1022–1024, 1991.PubMedCrossRefGoogle Scholar
  31. 31.
    Webb AR, Holick MF: The role of sunlight in the cutaneous production of vitamin D3. Annu Rev Nutr 8: 375–399, 1988.PubMedCrossRefGoogle Scholar
  32. 32.
    Kawashima H, Kraut JA, Kurokawa K: Metabolic acidosis suppresses 25-hydroxyvitamin D3 (alpha-hydroxylase in the rat kidney. J Clin Invest 70: 135–140, 1982.PubMedCrossRefGoogle Scholar
  33. 33.
    Bell NH: Vitamin D-endocrine system. J Clin Invest 76: 1–6, 1985.PubMedCrossRefGoogle Scholar
  34. 34.
    DeLuca HR: Metabolism and mechanism of action of vitamin D-1982. In: WA Peck, ed, Bone and Mineral Research Annual 1. Excerpta Medica, Princeton, pp 7–73, 1983.Google Scholar
  35. 35.
    Norman AW, Roth J, Orci L: The vitamin D endocrine system: steroid metabolism, hormone, receptors, and biological response (calcium binding proteins). Endocr Rev 3: 331–366, 1982.PubMedCrossRefGoogle Scholar
  36. 36.
    Gkonos Pi, London R, Hendler ED: Hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in a patient with end-stage renal disease and active tuberculosis. N Engl J Med 311: 1683–1685, 1984.CrossRefGoogle Scholar
  37. 37.
    Barbour GL, Coburn JW, Slatapolsky E, Norman AW, Horast RL: Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25dihydroxyvitamin D. N Engl J Med 305: 440–443, 1981.PubMedCrossRefGoogle Scholar
  38. 38.
    Zerwekh JE, Breslau NA: Human placental production of 1 alpha,25-dihydroxyvitamin D3: biochemical characterization and production in normal subjects and patients with pseudohypoparathyroidism. J Clin Endocrinol Metab 62: 192–196, 1986.PubMedCrossRefGoogle Scholar
  39. 39.
    Holtrop ME, Cox KA, Clark MB, Holick MF, Anast CS: 1,25-dihydroxycholicalciferol stimulates osteoclasts in rat bones in the absence of parathyroid hormone. Endocrinology 108: 2293–2301, 1981.PubMedCrossRefGoogle Scholar
  40. 40.
    Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A, Suda T: Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122: 1373–1382, 1988.PubMedCrossRefGoogle Scholar
  41. 41.
    Suda T, Takahashi N, Martin TJ: Modulation of osteoclast differentiation. Endocr Rev 13 (1): 66–80, 1992.PubMedGoogle Scholar
  42. 42.
    Mundy GR, Martin TJ: The hypercalcemia of malignancy: pathogenesis and management. Metabolism 31: 1247–1277, 1982.PubMedCrossRefGoogle Scholar
  43. 43.
    Case records of the Massachusetts General Hospital. N Engl J Med 225 (20): 789–791, 1941.CrossRefGoogle Scholar
  44. 44.
    Stewart AF, Horst R, Deftos LJ, Cadman EL, Lang K, Broadus AE: Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med 303: 1377–1383, 1980.PubMedCrossRefGoogle Scholar
  45. 45.
    Moseley JM, Kubota M, Diefenbach-Jagger H, Wettenhall REH, Kemp BE, Suva LJ, Rodda CP, Ebeling PR, Hudson PJ, Zajac JD, Martin TJ: Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA 84: 5048–5052, 1987.PubMedCrossRefGoogle Scholar
  46. 46.
    Burtis WJ, Wu T, Bunch C, Wysolmerski J, Insogna K, Weir E, Broadus AE, Stewart AF: Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclasestimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem 262(15):71517156, 1987.Google Scholar
  47. 47.
    Strewler GJ, Stern P, Jacobs J, Eveloff J, Klein RF, Leung SC, Rosenblatt M, Nissenson R: Parathyroid hormone-like protein from human renal carcinoma cells structural and functional homology with parathyroid hormone. J Clin Invest 80: 1803–1807, 1987.PubMedCrossRefGoogle Scholar
  48. 48.
    Suva LJ, Winslow GA, Wettenhall REH, Hammonds RG, Moseley JM, Dieffenbach-Jagger, Rodda C, Kemp BE, Rodriguez H, Chen E, Hudson PJ, Martin TJ, Wood WI: A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237: 893896, 1987.Google Scholar
  49. 49.
    Abou-Samra A, Juppner H, Force T, Freeman MW, Kong X, Schipani E, Urena P, Richards J, Bonventre JV, Potts JT, Kronenberg HM, Segre GV: Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proc Nail Acad Sci USA 89: 2732–2736, 1992.CrossRefGoogle Scholar
  50. 50.
    Horiuchi N, Caulfield M, Fisher JE, Goldman M, Mckee R, Reagan J, Levy J, Nutt R, Rodan S, Schoefield T, Clemens T, Rosenblatt M: Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 238: 1566–1568, 1987.PubMedCrossRefGoogle Scholar
  51. 51.
    Kemp BE, Moseley JM, Rodda CP, Ebeling PR, Wettenhall REH, Stapleton D, Dieffenbach-Jagger H, Ure F, Michelangeli BP, Simmons HA, Raisz LG, Martin TJ: Parathyroid hormone-related protein of malignancy: active synthetic fragments. Science 238: 1568–1570, 1987.PubMedCrossRefGoogle Scholar
  52. 52.
    Ebeling PR, Adam WR, Moseley JM, Martin TJ: Actions of synthetic parathyroid hormone-related protein (1–34) on the isolated rat kidney. J Endocrinol 120: 45–50, 1989.PubMedCrossRefGoogle Scholar
  53. 53.
    Yates AJP, Gutierrez GE, Smolens P, Travis PS, Katz MS, Auftemorte TB, Boyce BF, Hymer TK, Poser JW, Mundy GR: Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents. J Clin Invest 81: 932–938, 1988.PubMedCrossRefGoogle Scholar
  54. 54.
    Rizzoli F, Caverzasio J, Capuy MC, Martin TJ, Bonjour JP: Role of bone and kidney in parathyroid hormone-related peptideinduced hypercalcemia in rats. J Bone Miner Res 4 (5): 759–765, 1989.PubMedCrossRefGoogle Scholar
  55. 55.
    Sartori L, Weir EC, Stewart AF, Broadus AE, Mangin M, Barrett PQ, Insogna KL: Synthetic and partially-purified adenylate cyclase-stimulating proteins from tumors associated with humoral hypercalcemia of malignancy inhibit phosphate transport in a PTH-responsive renal cell line. J Clin Endocrinol Metab 66 (2): 459–461, 1987.CrossRefGoogle Scholar
  56. 56.
    Asa SL, Henderson J, Goltzman D, Drucker DJ: Parathyroid hormone-like peptide in normal and neoplastic human endocrine tissues J Clin Endocrinol Metab 71:1112–1118, 1990 Google Scholar
  57. 57.
    Thiede MA, Rodan GA: Expression of a calcium mobilizing parathyroid-like peptide in lactating mammary tissue Science 242:161, 1988 Google Scholar
  58. 58.
    Danks JA, Ebeling PR, Hayman J, Chou ST, Moseley JM, Dunlop J, Kemp BE, Martin TJ: Parathyroid hormone-related protein: immunohistochemical localization in cancers and in normal skin. J Bone Miner Res 4 (2): 273–278, 1989.PubMedCrossRefGoogle Scholar
  59. 59.
    Rodda CP, Kubota M, Heath JA, Ebeling PR, Moseley JM, Care AD, Caple IW, Martin Ti: Evidence for a novel parathyroid hormone-related protein in fetal lamb parathyroid glands and sheep placenta: comparisons with a similar protein in humoral hypercalcemia of malignancy. J Endocrinol 117: 261–271, 1988.PubMedCrossRefGoogle Scholar
  60. 60.
    Mallette LE: The parathyroid polyhormones: new concepts in the spectrum of peptide hormone action. Endocr Rev 12 (2): 110–117, 1991.PubMedCrossRefGoogle Scholar
  61. 61.
    Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC, Martin TJ: Localization of parathyroid hormone-related protein in breast cancer metastasis: increased incidence in bone compared with other sites. Cancer Res 51: 3059–3061, 1991.PubMedGoogle Scholar
  62. 62.
    Burtis WJ, Brady TF, Orloff JJ, Ersbak JB, Warrell RP, Olson BR, Wu T, Mitnick ME, Broadus AE, Stewart AF: Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 322: 1106–1112, 1990.PubMedCrossRefGoogle Scholar
  63. 63.
    Orloff JJ, Soifer NE, Fodero JP, Dann P, Burtis WJ: Accumulation of carboxy-terminal fragments of parathyroid hormone-related protein in renal failure. Kidney Int 43: 1371 1376, 1993.Google Scholar
  64. 64.
    Seymour JF, Gagel RF: Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin’s diesase and non-Hodgkin’s lymphoma. Blood 82 (5): 1383–1394, 1993.PubMedGoogle Scholar
  65. 65.
    Yashimoto K, Yamasaki R, Sakai H, Tezaka U, Takahshi M, Izuka M, Sekiya T, Saito S: Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 68 (5): 976–981, 1989.CrossRefGoogle Scholar
  66. 66.
    Nussbaum SR, Gaz R, Arnold A: Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 323: 1324–1328, 1990.PubMedCrossRefGoogle Scholar
  67. 67.
    Strewler GJ, Budayr AA, Clark OH, Nissenson RA: Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. J Clin Endocrinol Metab 76 (5): 1373–1375, 1993.PubMedCrossRefGoogle Scholar
  68. 68.
    Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, Mosely JM, Martin TJ: Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 73: 1309–1315, 1991.PubMedCrossRefGoogle Scholar
  69. 69.
    Garrett IR, Durk BGM, Nedwin GE, Mundy GR: Production of the bone resorbing cytokine lymphotoxin by cultured human myeloma cells. N Engl J Med 317: 526, 1987.PubMedCrossRefGoogle Scholar
  70. 70.
    Shaker JL, Krawczyk KW, Findling JW: Primary hyperparathyroidism and severe hypercalcemia with low circulating 1,25 dihydroxyvitamin D. J Clin Endocrino! Metab 71: 1305–1309, 1990.CrossRefGoogle Scholar
  71. 71.
    Stewart AF, Vignery A, Silvergate A, Ravin N, Livolsi V, Broadus AE, Baron R: Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 55: 219–227, 1982.PubMedCrossRefGoogle Scholar
  72. 72.
    Hosking DJ, Cowley A, Bucknall CA: Rehydration in the treatment of severe hypercalcemia. Q J Med 50: 473–481, 1981.PubMedGoogle Scholar
  73. 73.
    Nussbaum SR: Pathophysiology and management of severe hypercalcemia. Endocrino! Metab Clin North Am 22(2):343362, 1993.Google Scholar
  74. 74.
    Heath DA: Primary hyperparathyroidism: clinical presentation and factors influencing clinical management. Endocrinol Metab Clin North Am 18 (3): 631–646, 1989.PubMedGoogle Scholar
  75. 75.
    Consensus Development Conference Panel: Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Intern Med 114 (7): 593–597, 1991.CrossRefGoogle Scholar
  76. 76.
    Shane E, Bilezikian JP: Parathyroid carcinoma: a review of 62 patients. Endocr Rev 3: 218–226, 1982.PubMedCrossRefGoogle Scholar
  77. 77.
    Khosla S, Ebeling PR, Firek AF, Burritt MM, Kao PC, Heath H III: Calcium infusion suggests a “set point” abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. J Clin Endocrinol Metab 76: 715–720, 1993.PubMedCrossRefGoogle Scholar
  78. 78.
    Brown EM, Broadus AE, Brennan MF, et al.: Direct comparison in vivo and in vitro of suppressibility of parathyroid function of calcium in primary hyperparathyroidism. J Clin Endocrinol Metab 48: 604–610, 1979.PubMedCrossRefGoogle Scholar
  79. 79.
    Brown EM: Four-parameter model of the sigmoidal relaticnship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 56: 572–581, 1983.PubMedCrossRefGoogle Scholar
  80. 80.
    Arnold A, Kim HG, Gaz RD, Eddy RL, Fukushima R, Byers MG, Shows TB, Kronenberg HM: Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 83: 2034–2040, 1989.PubMedCrossRefGoogle Scholar
  81. 81.
    Arnold A, Staunton CE, Kim HG, Gaz RD, Kronenberg HM: Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Engl J Med 318: 658–662, 1988.PubMedCrossRefGoogle Scholar
  82. 82.
    Brandi ML, Aurbach GD, Fitzpatrick LA, Quarto R, Spiegel AM, Bliziotes MM, Norton JA, Doppman JL, Marx SJ: Parathyroid mitogenic activity in plasma from patients with familial multiple endocrine neoplasia type 1. N Engl J Med 314: 1287–1293, 1986.PubMedCrossRefGoogle Scholar
  83. 83.
    Beard CM, Heath H, O’Fallon WM, Anderson JA, Earler JD, Melton LJ: Therapeutic radiation and hyperparathyroidism: a case—control study in Rochester Minn. Arch Intern Med 149:1887–1890, 1989 Google Scholar
  84. 84.
    Parfitt AM, Braunstein GD, Katz A: Radiation-associated hyperparathyroidism: comparison of adenoma growth rates, inferred from weight and duration of latency, with prevalence of mitosis J Clin Endocrinol Metab 77:1318–1322, 1993 Google Scholar
  85. 85.
    Cohen J, Gierlowski TC, Schneider AB: A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. JAMA 264: 581–584, 1990.Google Scholar
  86. 86.
    Cryns VL, Thor A, Xu H-J, Shi-Xue H, Wierman ME, Vickery AL, Benedict WF, Arnold A: Loss of the retino-blastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 330: 757–761, 1994.PubMedCrossRefGoogle Scholar
  87. 87.
    Kassem M, XU C, Brask S, Eriksen EF, Mosekilde L, Kruse T: Familial isolated primary hyperparathyroidism. J Bone Miner Res 7 (Suppl 1): S249, 1992.Google Scholar
  88. 88.
    Wassif S, Moniz CF, Friedman E, Wong S, Weber G, Nordenskjold M, Peters TJ, Larsson C: Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 77: 1485–1489, 1993.PubMedCrossRefGoogle Scholar
  89. 89.
    Mundy GR, Cove DH, Fisken R: Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet 1: 1317–1320, 1980.PubMedCrossRefGoogle Scholar
  90. 90.
    Hellstrom J, Ivemark BI: Primary hyperparathyroidism. Acta Chir Scand 294 (Suppl): 1–133, 1962.Google Scholar
  91. 91.
    Melick RA, Henneman PH: Clinical and laboratory studies of 207 consecutive patients in a kidney stone clinic. N Engl J Med 259: 307–314, 1958.PubMedCrossRefGoogle Scholar
  92. 92.
    Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW: Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 6 (Suppl 2): S85 - S89, 1991.PubMedGoogle Scholar
  93. 93.
    Case records of the Massachusetts General Hospital: Weekly clinicopathological exercises. Case 14–1993. A 74-year-old woman with hyperparathyroidism and an osteolytic lesion in the humerus. N Engl J Med 328:1031–1035, 19…Google Scholar
  94. 94.
    Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM: Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism. Evidence for biphasic disease course. J Clin Endocrinol Metab 67: 1294–1298, 1988.PubMedCrossRefGoogle Scholar
  95. 95.
    Martin P, Bergmann P, Gillet C, Fuss M, Corvilain J, Van Geertruyden J: Long-term irreversibility of bone loss after surgery for primary hyperparathyroidism. Arch Intern Med 150 (7): 1495–1497, 1990.PubMedCrossRefGoogle Scholar
  96. 96.
    Patten BM, Bilezikian JP, Mallette LE, Prince A, Engle WK, Aurbach GD: Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med 80: 182–193, 1974.PubMedCrossRefGoogle Scholar
  97. 97.
    Turken SA, Cafferty M, Silverberg SJ, De La Cruz L, Cimino C, Lange DJ, Lovelace RE, Bilezekian JP: Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med 87: 553–557, 1989.PubMedCrossRefGoogle Scholar
  98. 98.
    Kleerekoper M, Bilezikian JP: A cure in search of a disease: parathyroidectomy for nontraditional features of primary hyperparathyroidism. Am J Med 96: 99–100, 1994.PubMedCrossRefGoogle Scholar
  99. 99.
    Solomon BL, Schaaf M, Smallridge RC: Psychologie symptoms before and after parathyroid surgery. Am J Med 96: 10 1106, 1994.Google Scholar
  100. 100.
    Mallette LE, Bilezikian JP, Heath DA, Aurbach GD: Primary hyperparathyroidism: clinical and biochemical features. Medicine 53: 127–146, 1974.PubMedCrossRefGoogle Scholar
  101. 101.
    Hollenberg AN, Arnold A: Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism. Am J Med 91 (5): 547–548, 1992.CrossRefGoogle Scholar
  102. 102.
    Eisenberg H, Pallotta J, Sacks B, Brickman AS: Parathyroid localization, three-dimensional modeling, and percutaneous ablation techniques. Endocrino! Metab Clin North Am 18 (3): 659–700, 1989.Google Scholar
  103. 103.
    Marcus R: Estrogens and progestins in the manangement of primary hyperparathyroidism. Endocrinol Metab Clin North Am 18 (3): 715–722, 1989.PubMedGoogle Scholar
  104. 104.
    Bilezikian JP: Clinical Review 51: management of hypercalcemia. J Clin Endocrinol Metab 77 (6): 1445–1449, 1993.PubMedCrossRefGoogle Scholar
  105. 105.
    Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy GR: Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 77: 1067–1071, 1993.PubMedCrossRefGoogle Scholar
  106. 106.
    Law W, Heath H III: Familial benign hypercalcemia (hypocalciuric hypercalcemia): clinical and pathogenetic studies in 21 families. Ann Intern Med 102: 511–519, 1985.PubMedCrossRefGoogle Scholar
  107. 107.
    Marx SJ, Attie MF, Levine MA, Spiegel AM, Downs RW, Lasker RD: The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. Medicine 60: 397–412, 1981.PubMedCrossRefGoogle Scholar
  108. 108.
    Chou Y-HW, Brown EM, Levi T, Crowe G, Atkinson AB, Arnquist HJ, Toss G, Fuleihan GE-H, Seidman JG, Seidman CE: The gene responsible for familial hypocalciuric hypercalcemia maps to chromosome 3q in four unrelated families. Nature Genet 1: 295–299, 1992.PubMedCrossRefGoogle Scholar
  109. 109.
    Orwoll E, Silbert J, McClung M: Asymptomatic neonatal familial hypercalcemia. Pediatrics 69: 109–111, 1982.PubMedGoogle Scholar
  110. 110.
    Marx SJ: Familial hypocalciuric hypocalcemia. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2nd ed. Raven Press, New York, pp 166–169, 1993.Google Scholar
  111. 111.
    Marx SJ, Attie MF, Spiegel AM, Levine MA, Lasker RD, Fox M: An association between neonatal severe primary hyperparathyroidism and familial hypocalciuric hypercalcemia in three kindreds. N Engl J Med 306: 257–264, 1982.PubMedCrossRefGoogle Scholar
  112. 112.
    Marx SJ, Fraser D, Rapoport A: Familial hypociciuric hypercalcemia: mild expression of the gene in heterozygotes and severe expression in homozygotes. Am J Med 62: 698706, 1985.Google Scholar
  113. 113.
    Pollak MR, Chou Y-H, Marx SJ, Steinmann B, Cole DEC, Brandi ML, Papapoulos SE, Menko F,Hendy GN, Brown EM, Seidman CE, Seidman JG: Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism: the effects of mutant gene dosage on phenotype. J Clin Invest,in press.Google Scholar
  114. 114.
    Marx SJ, Lasker RD, Brown EM, Fitzpatrick LA, Sweeney NB, Boldbloom RB, Gillis DA, Cole DE: Secretory dysfunction in parathyroid cells from a neonate with severe primary hyperparathyroidism. J Clin Endocrinol Metab 62: 445–449, 1986.PubMedCrossRefGoogle Scholar
  115. 115.
    Attie MF, Gill JR Jr, Stock JL, Spiegel AM, Downs RW Jr, Levine MA, Marx SJ: Urinary calcium excretion in familial hypocalciuric hypercalcemia. Persistence of relative hypocalciuria after induction of hypoparathyoidism. J Clin Invest 72: 667–676, 1983.PubMedCrossRefGoogle Scholar
  116. 116.
    Kristiansen JH, Rodbro P, Christiansen C, Johansen J, Jensen JT: Familial hypocalciuric hypercalcemia. III. bone mineral metabolism. Clin Endocrinol 26: 713–716, 1987.CrossRefGoogle Scholar
  117. 117.
    McMurtry CT, Schranck FW, Walkenhorst DA, Murphy WA, Kocher DB, Teitelbaum SL, Rupich RC, Whyte MP: Significant developmental elevation in serum parathyroid hormone levels in a large kindred with familial benign (hypocalciuric) hypercalcemia. Am J Med 93: 947–958, 1992.CrossRefGoogle Scholar
  118. 118.
    Marx SJ, Stock JL, Attie MF, Downs RW Jr, Gardner DG, Brown EM, Spiegel AM, Doppman JL, Brennan MF: Familial hypocalciuric hypercalcemia: recognition among patients referred after successful parathyroid exploration. Ann Intern Med 92: 351–356, 1980.PubMedCrossRefGoogle Scholar
  119. 119.
    Harrell GT, Fisher S: Blood chemical changes in Boeck’s sarcoid with particular reference to protein, calcium and phosphatase values. J Clin Invest 18: 687–693, 1939.PubMedCrossRefGoogle Scholar
  120. 120.
    Kozeny GA, Barbato AL, Bansal BK, Vertuno LL, Hano JE: Hypercalcemia associated with silicone-induced granulomas. N Engl J Med 311: 1103–1105, 1984.PubMedCrossRefGoogle Scholar
  121. 121.
    Kantarijian HM, Saad MF, Estey EH, Sellin RV, Samaan NA: Hypercalcemia in disseminated candidiasis. Am J Med 74: 721–724, 1983.CrossRefGoogle Scholar
  122. 122.
    Hoffman VH, Korzeniowski OM: Leprosy, hypercalcemia and elevated serum calcitriol levels. Ann Intern Med 105: 890891, 1986.Google Scholar
  123. 123.
    Adams JS: Vitamin D metabolite-mediated hypercalcemia. Endocrinol Metab Clin North Am 18 (3): 765–778, 1989.PubMedGoogle Scholar
  124. 124.
    Zaloga GP, Chernow B, Eil C: Hypercalcemia and disseminated cytomegalovirus injection in the acquired immunodeficiency syndrome. Ann Intern Med 102: 331–333, 1985.PubMedCrossRefGoogle Scholar
  125. 125.
    Ahmed B, Jaspan JB: Case report: hypercalcemia in a patient with AIDS and Pneumocystis carinii pneumonia. Am J Med Sci 306 (5): 313–316, 1993.PubMedCrossRefGoogle Scholar
  126. 126.
    Kimberg DV, Baerg RD, Gershon E: Effect of cortisone treatment on the active transport of calcium by the small intestine. J Clin Invest 50: 1309–1321, 1971.PubMedCrossRefGoogle Scholar
  127. 127.
    Meyrier A, Valeyre D, Bouillon R, Paillard F, Battesti J-P, Georges R: Resorptive versus absorptive hypercalciuria in sarcoidosis: correlations with 25-hydroxyvitamin D3 and 1,25dihydroxyvitamin D, and parameters of disease activity. Q J Med 54: 269–281, 1985.PubMedGoogle Scholar
  128. 128.
    Adams JS, Diz MM, Sharma OP: Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med 111: 437–438, 1989.PubMedCrossRefGoogle Scholar
  129. 129.
    Adams JS, Sharma OP, Diz MM, Endres DB: Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J Clin Endocrinol Metab 70: 1090–1095, 1990.PubMedCrossRefGoogle Scholar
  130. 130.
    Pont A: Unusual causes of hypercalcemia. Endocrinol Metab Clin North Am 18 (3): 753–764, 1989.PubMedGoogle Scholar
  131. 131.
    Mosekilde L, Eriksen Erik, Charles P: Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 19 (1): 35–63, 1990.PubMedGoogle Scholar
  132. 132.
    Mundy GR, Shapiro JL, Bandelin JG, Canalis EM, Raisz LG: Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 58: 529, 1976.PubMedCrossRefGoogle Scholar
  133. 133.
    Hedman I, Tisell L-E: Life-threatening hypercalcemia in a case of thyrotoxicosis. Acta Chir Scand 151: 487–489, 1985.PubMedGoogle Scholar
  134. 134.
    Rude RK, Oldham SB, Singer FR, Nicoloff JT: Treatment of thyrotoxic hypercalcemia with propranolol. N Engl J Med 294: 431–433, 1976.PubMedCrossRefGoogle Scholar
  135. 135.
    Loeb RF: Chemical changes in the blood in Addison’s disease. Science 76: 420–425, 1932.PubMedCrossRefGoogle Scholar
  136. 136.
    Muls E, Bouillon R, Boelaert J, Lamberigts G, Van Imschoot S, Daneels R, DeMoor P: Etiology of hypercalcemia in a patient with Addison’s disease. Calcif Tissue Int 34: 523–526, 1982.PubMedCrossRefGoogle Scholar
  137. 137.
    Plum F, Dunning NF: The effect of therapeutic mobilization on hypercalciuria following acute poliomyelitis. Arch Intern Med 101: 528–536, 1958.CrossRefGoogle Scholar
  138. 138.
    Stewart AF, Adler M, Byers CM, Segre GV, Broadus AE: Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med 306: 1136–1140, 1982.PubMedCrossRefGoogle Scholar
  139. 139.
    Meythaler JM, Tuel SM, Cross LL: Successful treatment of immobilization hypercalcemia using calcitonin and etidronate. Arch Phys Med Rehabil 74 (3): 316–319, 1993.PubMedGoogle Scholar
  140. 140.
    Varache N, Audran M, Clochon P, Lortholary A, Bouachow G, Alquier P, Basle MF: Aminohydroxypropyidene bisphosphonate treatment of severe immobilization hypercalcemia in a young patient. Clin Rheumatol 10 (3): 328–332, 1991.PubMedCrossRefGoogle Scholar
  141. 141.
    Gallacher SJ, Ralston SH, Dryburgh FJ, Logue FC, Allam BF, Boyce BF, Boyle IT: Immobilization-related hypercalcemia—a possible novel mechanism and response to pamidronate. Postgrad Med J 66 (781): 918–922, 1990.PubMedCrossRefGoogle Scholar
  142. 142.
    Hardt LL, Rivers AB: Toxic manifestations following the alkaline treatment of peptic ulcer. Arch Intern Med 31: 17 1180, 1923.Google Scholar
  143. 143.
    Kapener P, Langsdorf L, Marcus R, Kraemer FB, Hoffman AR: Milk-alkali syndrome in patients treated with calcium carbonate after cardiac transplantation. Arch Intern Med 146: 1965–1968, 1986.CrossRefGoogle Scholar
  144. 144.
    Abreo K, Adlakha A, Kilpatrick S, flanagan R, Webb R, Shakamuri S: The milk-alkali syndrome. A reversible form of acute renal failure. Arch Intern Med 153: 1005–1010, 1993.PubMedCrossRefGoogle Scholar
  145. 145.
    Jacobs TP: The milk-alkali syndrome. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2nd ed. Raven Press, New York, p 181, 1993.Google Scholar
  146. 146.
    Orwoll ES: The milk-alkali syndrome: current concepts. Ann Intern Med 97: 242–248, 1982.PubMedCrossRefGoogle Scholar
  147. 147.
    Davies M, Mawer EB, Freemont AJ: The osteodystrophy of hypervitaminosis D: a metabolic study. Q J Med 61: 911–919, 1986.PubMedGoogle Scholar
  148. 148.
    Rodahl K, Moore T: The vitamin A content and toxicity of bear and seal liver. Biochem J 37: 166–168, 1943.PubMedGoogle Scholar
  149. 149.
    Valente JD, Elias AN, Weinstein GD: Hypercalcemia associated with oral isotretinoin in the treatment of severe acne. JAMA 250: 1899, 1983.Google Scholar
  150. 150.
    Villablanca JG, Khan AA, Avramis VI, Reynolds CP: Hypercalcemia: a dose-limiting toxicity associated with 13cis-retinoic acid. Am J Pediatr Hematol Oncol 15 (4): 410–415, 1993.PubMedGoogle Scholar
  151. 151.
    Sakaibara M, Ichikawa M, Amano Y, Matsuzawa S, Agematsu K, Mori T, Koike K, Nakahata T, Komiyama A: Hypercalcemia associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Leuk Res 17 (5): 441–443, 1993.CrossRefGoogle Scholar
  152. 152.
    Fell HB, Mellanby E: Effect of hypervitaminosis A on foetal mouse bones cultivated in vitro. Br Med J 2: 535–539, 1950.PubMedCrossRefGoogle Scholar
  153. 153.
    Oreffo RO, Teti A, Triffitt JT, Francis MJ, Carano A, Zallone AZ: Effect of Vitamin A on bone resorption: evidence for direct stimulation of isolated chicken osteoclasts by retinol and retinoic acid. J Bone Miner Res 3: 203–210, 1988.PubMedCrossRefGoogle Scholar
  154. 154.
    Parfitt AM: Chorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. N Engl J Med 281: 55–59, 1969.PubMedCrossRefGoogle Scholar
  155. 155.
    Parfitt AM: The interactions of thiazide diuretics with parathyroid hormone and vitamin D. J Clin Invest 51: 1879–1888, 1972.PubMedCrossRefGoogle Scholar
  156. 156.
    Christensson T, Hellstrom K, Wengle B: Hypercalcemia and primary hyperparathyroidism: prevalence in patients receiving thiazides as detected in a health screen. Arch Intern Med 137: 1138–1142, 1977.PubMedCrossRefGoogle Scholar
  157. 157.
    Porter RH, Cox BG, Heaney D, Hostetter TH, Stinebaugh BJ, Suki WN: Treatment of hypoparathyroid patients with chlorthalidone. N Engl J Med 298: 577, 1978.PubMedCrossRefGoogle Scholar
  158. 158.
    Mallette LE, Eichhorn E: Effects of lithium carbonate on human calcium metabolism. Arch Intern Med 146(4):770776, 1986.Google Scholar
  159. 159.
    Salata R, Klein I: Effects of lithium on the endocrine system: a review. J Lab Clin Med 110 (2): 130–136, 1987.PubMedGoogle Scholar
  160. 160.
    Mallette LE, Kouri K, Zengotita H, Hollis BW, Malini S: Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. J Clin Endocrinol Metab 68 (3): 654–660, 1989.PubMedCrossRefGoogle Scholar
  161. 161.
    Speigel AM, Rudorfer MV, Marx SJ, Linnoila M: The effect of short-term lithium administration on suppressibility of parathyroid hormone secretion by calcium in vivo. J Clin Endocrinol Metab 59: 354, 1984.CrossRefGoogle Scholar
  162. 162.
    Brown EM: Lithium induces abnormal calcium regulated PTH release in dispersed bovine parathyroid cells. J Clin Endocrinol Metab 52: 1046, 1981.PubMedCrossRefGoogle Scholar
  163. 163.
    Wallace J, Scarpa A: Similarities of Li+ and low Ca++ on the modulation of secretion by parathyroid cells in vitro. J Biol Chem 258: 6280–6286, 1983.Google Scholar
  164. 164.
    Norderstrom J, Sturgard K, Perbeck L, Willems J, BagedahlStrindlund M, Linder J: Hyperparathyroidism associated with the treatment of manic-depressive disorders by lithium. Eur J Surg 158 (4): 207–211, 1992.Google Scholar
  165. 165.
    McPherson ML, Prince SR, Atamer ER, Maxwell DB, RossClunis H, Estep HL: Theophylline-induced hypercalcemia. Ann Intern Med 105 (1): 52–54, 1986.PubMedCrossRefGoogle Scholar
  166. 166.
    de Torrente A, Berl T, Chon PD, Kawamoto E, Hertz P, Schrier RW: Hypercalcemia of acute renal failure. Am J Med 61: 119–123, 1976.PubMedCrossRefGoogle Scholar
  167. 167.
    Meneghini LF, Oster JR, Camacho JR, Gkonos PJ, Roos BA: Hypercalcemia in association with acute renal failure and rhabdomyolysis. Case report and literature review. Miner Electrolyte Metab 19: 1–16, 1993.PubMedGoogle Scholar
  168. 168.
    Hadjis T, Grieff M, Lockhat D, Kaye M: Calcium metabolism in acute renal failure due to rhabdomyolysis. Clin Nephrol 39: 22–27, 1993.PubMedGoogle Scholar
  169. 169.
    Lane JT, Boudreau RJ, Kinlaw WB: Disappearance of muscular calcium deposits during resolution of prolonged rhabdomyolysis-induced hypercalcemia. Am J Med 89: 523525, 1990.Google Scholar
  170. 170.
    Llach F, Felsenfeld AJ, Haussier MR: The pathophysiology of altered calcium metabolism in rhabdomyolysis-induced acute renal failure. N Engl J Med 305: 117–123, 1981.PubMedCrossRefGoogle Scholar
  171. 171.
    Argiles A, Kerr PG, Canaud B, Flavier JL, Mion C: Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int 43: 630–640, 1993.PubMedCrossRefGoogle Scholar
  172. 172.
    Traindl O, Langle F, Reading S, Franz M, Watschinger B, Klauser R, Woloszczuk W, Kovarik J: Secondary hyperparathyroidism and acute tubular necrosis following renal transplantation. Nephrol Dial Transplant 8: 173–176, 1993.PubMedGoogle Scholar
  173. 173.
    Williams JCP, Barratt-Boyes BG, Lowe JB: Supravalvular aortic stenosis. Circulation 24: 891–896, 1961.CrossRefGoogle Scholar
  174. 174.
    Black JA, Bonham Carter RE: Association between aortic stenosis and facies of severe infantile hypercalcaemia. Lancet ii:745–749, 1963.Google Scholar
  175. 175.
    Garcia RE, Friedman WF, Kabach MM, et al.: Idiopathic hypercalcemia and supravalvular aortic stenosis: documentation of a new syndrome. N Engl J Med 271: 117–120, 1964.PubMedCrossRefGoogle Scholar
  176. 176.
    Taylor AB, Stern PH, Bell NH: Abnormal regulation of circulation 25-hydroxyvitamin D in the Williams syndrome. N Engl J Med 306: 972–975, 1982.PubMedCrossRefGoogle Scholar
  177. 177 Langman CB: Hypercalcemic syndromes in infants and children. In: Primer on metabolic bone diseases and disorders of mineral metabolism,2nd ed. Raven Press, New York, pp 182184, 1993.Google Scholar
  178. 178.
    Kruse K, Pankau R, Gosch A, Wohlfahrt K: Calcium metabolism in Williams-Beuren syndrome. J Pediatr 121: 902–907, 1992.PubMedCrossRefGoogle Scholar
  179. 179.
    Martin NDT, Snodgrass GJ, Cohen RD: Idiopathic infantile hypercalcemia—a continuing enigma. Arch Dis Child 59: 605–613, 1984.PubMedCrossRefGoogle Scholar
  180. 180.
    Langman CB, Budayr AA, Sailer DE, Strewler GJ: Nonmalignant expression of parathyroid hormone-related protein is responsible for idiopathic infantile hypercalcemia. J Bone Miner Res 7: S93 2A, 1992.Google Scholar
  181. 181.
    Khosla S, van Heerden JA, Gharib H, Jackson IT, Danks J, Hayman JA, Martin TJ: Parathyroid hormone-related protein and hypercalcemia secondary to massive mammary hyperplasia. N Engl J Med 322: 1157, 1990.PubMedGoogle Scholar
  182. 182.
    Lepre F, Grill V, Martin TJ: Hypercalcemia in pregnancy and lactation associated with parathyroid hormone-related protein. N Engl J Med 328: 666–667, 1993.PubMedCrossRefGoogle Scholar
  183. 183.
    Bilezikian JP: Management of acute hypercalcemia. N Engl J Med 326: 1196–1203, 1992.PubMedCrossRefGoogle Scholar
  184. 184.
    Suki WN, Yium JJ, Von Minden M, Saller-Hebert C, Eknoyan G, Martinez-Maldonado M: Acute treatment of hypercalcemia with furosemide. N Engl J Med 283: 836–840, 1970.PubMedCrossRefGoogle Scholar
  185. 185.
    fleisch H: Bisphosphonates: pharmacology and use in the treatment of tumor-induced hypercalcemia and metastatic bone disease. Drugs 42: 919–944, 1991.PubMedCrossRefGoogle Scholar
  186. 186.
    Singer FR, Ritch PS, Lad TE, Ringenberg QS, Schiller JH, Recker RR, Ryzen E: Treatment of hypercalcemia of malignancy with intravenous etidronate—a controlled, multicenter study. Arch Intern Med 151: 471–476, 1991.PubMedCrossRefGoogle Scholar
  187. 187.
    Gucalp R, Ritch P, Wiernik PH, et al.: Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 10: 134142, 1992.Google Scholar
  188. 188.
    Kanis JA, Urwin GH, Gray RE, Beneton MN, McCloskey EV, Hamdy NA, Murray SA: Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med 82 (Suppl 2A): 55–70, 1987.PubMedCrossRefGoogle Scholar
  189. 189.
    Nussbaum SR, Younger J, VandePol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE: Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90 mg dosages. Am J Med 95: 297–304, 1993.PubMedCrossRefGoogle Scholar
  190. 190.
    Gurney H, Grill V, Martin TJ: Parathyroid hormone-related protein and response to pamidronate to tumour-induced hypercalcaemia. Lancet 341: 1611–1613, 1993.PubMedCrossRefGoogle Scholar
  191. 191.
    Dodwell DJ, Abbas SK, Morton AR, Howell A: Parathyroid hormone-related protein°°-69) and response to pamidronate therapy for tumour-induced hypercalcaemia. Eur J Cancer 27: 1629–1633, 1991.PubMedCrossRefGoogle Scholar
  192. 192.
    Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle ITK, Boyce BF: Mineralisation defects with pamidronate therapy for Paget’s disease. Lancet 342: 1459–1460, 1993.PubMedCrossRefGoogle Scholar
  193. 193.
    Binstock MD, Mundy GR: Effect of calcitonin and glucocorticoids in combination of the hypercalcemia of malignancy. Ann Intern Med 93: 269–272, 1980.PubMedCrossRefGoogle Scholar
  194. 194.
    Thiebaud D, Jacquet AF, Burckhardt P: Fast and effective treatment of malignant hypercalcemia. Arch Intern Med 150: 2125–2128, 1990.PubMedCrossRefGoogle Scholar
  195. 195.
    Physicians Desk Reference,48 ed. Medical Economics Data, Montvale, NJ, pp 1847–1848, 1994.Google Scholar
  196. 196.
    Brown JH, Kennedy BJ: Mithramycin in the treatment of disseminated testicular neoplasms. N Engl J Med 272: 11 1118, 1965.Google Scholar
  197. 197.
    Yarbro JW, Kennedy BJ, Barnum CP: Mithramycin inhibition of ribonucleic acid synthesis. Cancer Res 26: 36–39, 1966.PubMedGoogle Scholar
  198. 198.
    Ray R, Snyder RC, Thomas S, Koller CA, Miller DM: Mithramycin blocks protein binding and function of the SV40 early promoter. J Clin Invest 83: 2003–2007, 1989.PubMedCrossRefGoogle Scholar
  199. 199.
    Warrell RP Jr, Bockman RS, Coonley CJ, Isaacs M, Staszewski H: Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 73: 1487–1490, 1984.PubMedCrossRefGoogle Scholar
  200. 200.
    Warrell RP Jr, Israel R, Frisone M, Snyder T, Gaynor JJ, Bockman RS: Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, doubleblind comparison to calcitonin. Ann Intern Med 108: 669–674, 1988.PubMedCrossRefGoogle Scholar
  201. 201.
    Physicians Desk Reference,48 ed. Medical Economics Data, Montvale, NJ, pp 968–969, 1994.Google Scholar
  202. 202.
    Mundy GR, Wilkinson R, Heath DA: Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med 74: 421–432, 1983.PubMedCrossRefGoogle Scholar
  203. 203.
    Mundy GR, Rick ME, Turcotte R, Kowalski MA: Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy. Am J Med 65: 600606, 1978.Google Scholar
  204. 204.
    Zerwekh JE, Pak CYC, Kaplan RA, McGuire JL, Upchurch K, Breslau N, Johnson RJ: Pathogenic role of 1 a,25- dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria: different response to prednisolone therapy. J Clin Endocrinol Metab 51: 381–386, 1980.PubMedCrossRefGoogle Scholar
  205. 205.
    Lukert BP, Raisz LG: Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112: 352–364, 1990.PubMedCrossRefGoogle Scholar
  206. 206.
    Ayala G, Chertow BS, Shah JH, Williams GA, Kukreja SC: Acute hyperphosphatemia and acute persistent renal insufficiency induced by oral phosphate therapy. Ann Intern Med 83: 520–521, 1975.PubMedCrossRefGoogle Scholar
  207. 207.
    Dudley FJ, Blackburn CRB: Extraskeletal calcification complicating oral neurophosphate therapy. Lancet ii:628–630, 1970.Google Scholar
  208. 208.
    Carey RW, Schmitt GW, Kopald HH: Massive extraskeletal calcification during phosphate treatment of hypercalcemia. Arch Intern Med 122: 150–155, 1968.PubMedCrossRefGoogle Scholar
  209. 209.
    Gagel RF: Laboratory values of importance for calcium metabolism and metabolic bone disease. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2nd ed. Raven Press, New York, p 211, 1993.Google Scholar
  210. 210.
    Stewart AF, Battaglini-Sabetta J, Millstone L: Hypocalcemia-induced pustular psoriasis of Von Zumbusch, new experience with an old syndrome. Ann Intern Med 100: 677–680, 1984.PubMedCrossRefGoogle Scholar
  211. 211.
    Rimailho A, Bouchard P, Schaison G: Improvement of hypocalcemic cardiomyopathy by correction of serum calcium level. Am Heart J 109: 611, 1985.PubMedCrossRefGoogle Scholar
  212. 212.
    Nuefeld M, Maclaren NK, Blizzard RM: Two types of autoimmune Addison’s disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine 60: 355–362, 1981.CrossRefGoogle Scholar
  213. 213.
    Anast CS, Mohs JM, Kaplan SI, Burns TW: Evidence of parathyroid failure in magnesium deficiency. Science 177: 606–608, 1972.PubMedCrossRefGoogle Scholar
  214. 214.
    Anast CS, Winnacker JL, Forte LF, Burns TW: Impaired release of parathyroid hormone in magnesium deficiency. J Clin Endocrinol Metab 42: 707–717, 1976.PubMedCrossRefGoogle Scholar
  215. 215.
    Cholst IN, Steinberg SF, Tropper PJ, Fox HE, Segre GV, Bilezikian JP: The influence of hypermagnesemia on serum calcium and parathyroid hormone levels. N Engl J Med 301: 1221–1225, 1984.CrossRefGoogle Scholar
  216. 216.
    Rude RK, Oldham SB, Singer FR: Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. Clin Endocrinol 5: 209–224, 1976.CrossRefGoogle Scholar
  217. 217.
    Rude RK: Magnesium metabolism and deficiency. Endocrinol Metab Clin North Am 22: 377–395, 1993.PubMedGoogle Scholar
  218. 218.
    Shah GM, Alvarado P, Kirschenbaum MA: Symptomatic hypocalcemia and hypomagnesemia with renal magnesium wasting associated with pentamidine therapy in a patient with AIDS. Am J Med 89: 380–382, 1990.PubMedCrossRefGoogle Scholar
  219. 219.
    Barton CH, Pahl M, Vaziri ND, Cesario T: Renal magnesium wasting associated with amphotericin B therapy. Am J Med 77: 471–474, 1984.PubMedCrossRefGoogle Scholar
  220. 220.
    Burch WM, Posillico JT: Hypoparathyroidism after I-131 therapy with subsequent return of parathyroid function. J Clin Endocrinol Metab 57: 398–401, 1983.PubMedCrossRefGoogle Scholar
  221. 221.
    Richards GE, Brewer ED, Conley SB, Saldana LR: Combined hypothyroidism and hypoparathyroidism in an infant after maternal 131-Iodine administration. J Pediatr 99: 14 1143, 1981.Google Scholar
  222. 222.
    Levine MA: Parathyroid hormone resistance syndromes. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2nd ed. Raven Press, New York, pp 194–200, 1993.Google Scholar
  223. 223.
    Albright F, Burnett CH, Smith PH, et al.: Pseudohypoparathyroidism: an example of Seabright-Bantam syndrome: report of three cases. Endocrinology 30: 922–932, 1942.Google Scholar
  224. 224.
    Albright F, Forbes AP, Henneman PH: Pseudopseudohypoparathyroidism. Trans Assoc Am Physicians 65: 337350, 1952.Google Scholar
  225. 225.
    Levine MA Ahn TG, Klupt SF, Kaufman KD, Smallwood PM, Bourne HR, Sullivan KA, Van Dop C: Genetic deficiency of the alpha subunit of the guanine nucleotide-binding protein Gs as the molecular basis for Albright hereditary osteodystrophy. Proc Natl Acad Sci USA 85: 617621, 1988.Google Scholar
  226. 226.
    Levine MA, Jap TS, Mauseth RS, Downs RW, Spiegel AM: Activity of the stimulatory guanine nucleotide-binding protein is reduced in erythrocytes from patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism: biochemical, endocrine, and genetic analysis of Albright’s hereditary osteodystrophy in six kindreds. J Clin Endocrinol Metab 62: 497–502, 1986.PubMedCrossRefGoogle Scholar
  227. 227.
    Weinstein LS, Gejman PV, Friedman E, Kadowaki T, Collins RM, Gershon ES, Spiegel AM: Mutations of the Gs alpha-subunit gene in Albright hereditary osteodystrophy detected by denaturing gradient gel electrophoresis. Proc Natl Acad Sci USA 87: 8287–8290, 1990.PubMedCrossRefGoogle Scholar
  228. 228.
    Patten JL, Johns DR, Valle D, Eil C, Gruppuso PA, Steele G, Smallwood PM, Levine MA: Mutation in the gene encoding the stimulatory G protein of adenylate cyclasc in Albright’s hereditary osteodystrophy. N Engl J Med 322: 1412–1419, 1990.PubMedCrossRefGoogle Scholar
  229. 229.
    Kidd GS, Schaaf M, Adler RA, Lassman MN, Wray HL: Skeletal responsiveness in pseudohypoparathyroidism: a spectrum of clinical disease. Am J Med 68:772 781, resistance to 1,25-dihydroxyvitamin D. Am J Med 83:984–1980. 990, 1987.Google Scholar
  230. 230.
    Murray TM, Rao LG, Wong MM, Waddell JP, McBroom R, 241. Tofalletti J, Nissenson RA, Endres D, McGarry E, Mogollon Tam CS, Rosen F, Levine MA: Pseudohypoparathyroidism G: Influence of continuous infusion of citrate on responses with osteitis fibrosa cystica: direct demonstration of skeletal of immuno-reactive PTH, calcium, magnesium components, responsiveness to parathyroid hormone in cells cultured from and other electrolytes in normal adults during plasmap- bone. J Bone Miner Res 8:83–91, 1993. heresis. J Clin Endocrinol Metab 60: 874–879, 1985.CrossRefGoogle Scholar
  231. 231.
    Chase LR, Melson GL, Aurbach GD: Pseudohypoparathy- 242. Mallette LE, Gomez LS: Systemic hypocalcemia after clinical roidism: defective excretion of 3’,5’-AMP in response to par injection of radiographic contrast media: amelioration by athyroid hormone. J Clin Invest 48:1832–1844, 1969. omission of calcium chelating agents. Radiology 147:677–679Google Scholar
  232. 232.
    Mallette LE, Kirkland JL, Gagel RF, Law WM Jr, Heath H 1982. III: Synthetic human parathyroid hormone-(1–34) for the 243. Gessner BD, Beller M, Middaugh JP, Whitford GM: Acute study of pseudohypoparathyroidism. J Clin Endocrinol fluoride poisoning from a public water system. N Engl J Med Metab 67:964–972, 1988. 330: 95–99, 1994.Google Scholar
  233. 233.
    Weinstein RS, Bryce GR, Sappington LJ, King DW, 244. Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Gallagher BB: Decreased serum ionized calcium and normal Portale AA: Foscarnet-induced hypocalcemia and effects of vitamin D metabolite levels with anti-convulsant drug treat foscarnet on calcium metabolism. J Clin Endocrinol Metab ment. J Clin Endocrinol Metab 58:1003–1009, 1984. 72: 1130–1135, 1991.Google Scholar
  234. 234.
    McCarthy JT, Kumar R: Renal osteodystrophy. Endocrinol 245. Gearhart MO, Sorg TB: Foscarnet-induced severe hypo- Metab Clin North Am 19:65–93, 1990. magnesemia and other electrolyte disorders. Ann Phar- Google Scholar
  235. 235.
    Hughes MR, Malloy PJ, Kieback DG, Kesterson RA, Pike macother 27:285–289, 1993. JW, Feldman E, O’Malley BW: Point mutations in the hu- 246. Grinspoon SK, Bilezikian JP: HIV disease and the endocrine man vitamin D receptor gene associated with hypocalcemic system. N Engl J Med 327:1360–1365, 1992. rickets. Science 242:1702–1705, 1988. 247. Raskin P, McClain CJ, Medsger TA Jr: Hypocalcemia associ-Google Scholar
  236. 236.
    Sone T, Marx SJ, Liberman UA, Pike JW: A unique point ated with metastatic bone disease. Arch Intern Med 132:539- mutation in the human vitamin D receptor chromosomal 543, 1973. gene confers hereditary resistance to 1,25-dihydroxyvitamin 248. Zusman J, Brown DM, Nesbit ME: Hyperphosphatemia, D3. Mol Endocrinol 4:623–631, 1990. hyperphosphaturia and hypocalcemia in acute lymphoblasticGoogle Scholar
  237. 237.
    Ritchie HH, Hughes MR, Thompson ET, Hochberg Z, leukemia. N Engl J Med 289:1335–1340, 1973. Feldman D, Pike JW, O’Malley BW: An ochre mutation 249. Kumar R: The metabolism and mechanism of action of 1,25in the vitamin D receptor gene causes hereditary 1,25 dihydroxyvitamin D. Kidney Int 30:793–803, 1986. dihydroxyvitamin-D3 resistant rickets in three families. Proc 250. Stewart AF, Longo W, Kreutter D, Jacob R, Burtis WJ: Natl Acad Sci USA 86:9783–9787, 1989. Hypocalcemia due to calcium soap formation in a patientGoogle Scholar
  238. 238.
    Liberman UA, Marx SJ: Vitamin D dependent rickets. In: with a pancreatic fistula. N Engl J Med 315:496–498, 1986. Primer on the Metabolic Bone Diseases and Disorders of 251. Tohme JF, Bilezikian JP: Hypocalcemic emergencies. Mineral Metabolism,2nd ed. Raven Press, New York, pp Endocrinol Metab Clin North Am 22:363–375, 1993. 274–279, 1993. 252. Breslau NA, Zerwekh JE: Relationship of estrogen and preg-Google Scholar
  239. 239.
    Balsan S, Garabedian M, Larchet M, Gorski AM, Cournot nancy to calcium homeostasis in pseudohypoparathyroidism. G, Tau C, Bourdeau A, Silve C, Ricour C: Long-term noctur J Clin Endocrinol Metab 62:45–51, 1986. nal calcium infusions can cure rickets and promote normal 253. Recker R: Calcium absorption and achlorhydria. N Engl J mineralization in hereditary resistance to 1,25-dihydroxy Med 313:70–73, 1985. vitamin D. J Clin Invest 77:1661–1667, 1986. 254. Kurzel RB, Hagen GA: Use of thiazide diuretics to reduceGoogle Scholar
  240. 240.
    Weisman Y, Bab I, Gazit D, Spirer Z, Jaffe M, Hochberg Z: the hypercalciuria of hypoparathyroidism during pregnancy. Long-term intracaval calcium infusion therapy in end-organ Am J Perinatol 7: 333–336, 1990.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Theresa A. Guise
    • 1
  • Gregory R. Mundy
    • 2
  1. 1.Division of EndocrinologyUniversity of Texas Health Science Center at San AntonioSan AntonioUSA
  2. 2.Department of MedicineUniversity of Texas Health Science Center at San AntonioSan AntonioUSA

Personalised recommendations